LOS ANGELES, May 26, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it will be participating in two upcoming investor conferences in June. Linda Marbán, Ph.D., Chief Executive Officer of Capricor will provide a company overview and update on its clinical development programs.

  • Jefferies 2015 Healthcare Conference, June 1, 2015, 10:30 a.m. EDT, in New York City; a webcast of this presentation will be available on Capricor's website at http://capricor.com/news/events/
  • The JMP Securities Life Sciences Conference, June 23, 2015, 12:00 p.m. EDT, in New York City

About Capricor Therapeutics

Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company with expertise in the field of cardiovascular disease aiming to develop novel therapies for diseases with significant unmet medical needs. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: Cenderitide, a natriuretic peptide receptor agonist, and CAP-1002, a cardiac cell therapy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.

CONTACT: Corporate Contact
         Capricor Therapeutics, Inc.
         AJ Bergmann, Vice President of Finance
         +1-310-358-3200
         abergmann@capricor.com
         
         Media Relations
         Russo Partners
         Christopher Hippolyte
         +1-646-942-5634
         chris.hippolyte@russopartnersllc.com
         
         Investor Relations:
         Russo Partners
         Robert Flamm, Ph.D.
         +1-212-845-4226
         robert.flamm@russopartnersllc.com

Capricor Therapeutics logo